...
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >A reappraisal of the role of vesicourethral anastomosis biopsy in patient candidates for salvage radiation therapy after radical prostatectomy.
【24h】

A reappraisal of the role of vesicourethral anastomosis biopsy in patient candidates for salvage radiation therapy after radical prostatectomy.

机译:重新评估膀胱尿道吻合活检在根治性前列腺切除术后抢救性放射治疗患者中的作用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND AND PURPOSE: To investigate the usefulness of vesicourethral anastomotic biopsy (VUBx) in patients who are candidates for salvage radiotherapy (SalvRT) after radical prostatectomy (RRP). MATERIAL AND METHODS: From 1992 to 2001, 98 patients with a PSA failure (PSAf) after RRP underwent SalvRT to the prostatic bed (median dose 70 Gy). In 50/98 patients the VUBx was positive, in 26 negative; 22 patients underwent SalvRT without a prior VUBx. The prognostic impact on biochemical disease-free survival (bNEDs) of histologic confirmation of the local failure was evaluated retrospectively. RESULTS: In the 40 patients with pre-RT PSA < or = 0.9 ng/mL, no additional prognostic information derived from the VUBx, while, for higher PSA values, a positive histology resulted as a covariate independently predictive of post-RT outcome (5-year bNEDs: 74% vs 42% in the 35 and 23 patients with a positive or negativeot performed VUBx, respectively, P=.03), together with pT, pre-RT PSA < or = 1.5 ng/mL, and PSAdoubling time. CONCLUSIONS: In case of PSAf after RRP, VUBx before SalvRT seems unnecessary for PSA < or = 0.9 ng/mL. For higher values, a positive VUBx seems to always justify a SalvRT, which may not be recommendable, given the nonnegligible risk of an already micrometastatic disease, if the biopsy results are negative.
机译:背景与目的:探讨膀胱尿道吻合口活检(VUBx)在根治性前列腺切除术(RRP)后进行抢救放疗(SalvRT)的患者中的有效性。材料与方法:从1992年至2001年,对98例RRP后发生PSA衰竭(PSAf)的患者进行了SalvRT到前列腺床的治疗(中位剂量为70 Gy)。在50/98例患者中,VUBx呈阳性,26例呈阴性; 22例患者接受了SalvRT,但未接受VUBx治疗。回顾性评估局部失败的组织学确认对生化无病生存期(bNEDs)的预后影响。结果:在40例RT前PSA <或= 0.9 ng / mL的患者中,没有从VUBx获得更多的预后信息,而对于更高的PSA值,由于协变量独立地预测了RT后的结果,组织学阳性5年bNED:分别为35例和23例VUBx阳性或阴性/未进行VUBx的患者分别为74%和42%(P = .03),以及pT,RT-RT PSA <或= 1.5 ng / mL,和PSA翻倍的时间。结论:对于RRP后的PSAf,对于PSA <或= 0.9 ng / mL,似乎不需要SalvRT之前的VUBx。对于更高的值,如果活检结果为阴性,鉴于已经存在微转移性疾病的风险不可忽略,那么阳性VUBx似乎总是证明SalvRT是合理的,这可能不值得推荐。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号